According to ZS research, two years into the COVID-19 pandemic, physicians in Europe say they’re only having about three-fourths as many interactions with pharmaceutical company representatives as they had pre-pandemic. They also say they’re more satisfied with in-person interactions than remote interactions, and their satisfaction with these virtual interactions has fallen, despite more experience with digital engagement tools.


We offer insights into where pharma can improve their interactions with physicians in Europe and areas where these physicians say they welcome support, including remote patient monitoring (RPM), digital health solutions and telehealth.


ZS has been conducting ongoing research to explore how physicians in Europe are engaging with pharmaceutical company representatives and how these interactions are evolving throughout the pandemic. The data we’ve captured in this infographic represents customer insights from 400 physicians in France, Germany, Italy, Spain and the U.K., who were surveyed in September 2021 and again in March 2022. In both surveys, we also included approximately 350 patients in Europe who cited similar challenges with digital health that the physicians are experiencing.